Experimental cell therapy takes on Hard-to-Treat blood cancers
NCT ID NCT04155710
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tested a new cell therapy called IOV-2001 in 7 patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that had stopped responding to standard drugs. The therapy uses a patient's own immune cells, which are collected, processed, and then infused back along with interleukin-2 to boost their activity. The main goals were to find the right dose and check for safety and any signs of tumor shrinkage.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
IOV-2001 (a cell therapy made from the patient's own immune cells) followed by interleukin-2 (IL-2)
What this could lead to
If successful, this could offer a new treatment option for patients with CLL or SLL that has stopped responding to standard drugs like ibrutinib.
What could go wrong
This was a very early, small trial (only 7 people) with no published results yet. Cell therapies can cause serious side effects, and it is unclear if this approach will work better than existing treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Allegheny Health
Pittsburgh, Pennsylvania, 15224, United States
-
Baptist Cancer Center
Memphis, Tennessee, 38120, United States
-
Duke University
Durham, North Carolina, 27710, United States
-
Moffitt Cancer Center
Tampa, Florida, 33612, United States
-
Ohio State University
Columbus, Ohio, 43210, United States
-
University of Cincinnati Medical Center
Cincinnati, Ohio, 45219, United States
-
University of Utah, Huntsman Cancer Institute
Salt Lake City, Utah, 84112, United States